Physician profile
Vipul D Ganatra
NPI 1093769689
$151,193.16
in general payments reported to CMS, 2019-2025
12 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $6,916 · 2021: $4,546 · 2022: $10K · 2023: $21K · 2024: $33K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,240 · Food and Beverage: $5,911 · Consulting Fee: $5,063 · Travel and Lodging: $4,469 · Education: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,065.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,240.00 |
| Food and Beverage | $5,911.32 |
| Consulting Fee | $5,062.50 |
| Travel and Lodging | $4,468.78 |
| Education | $452.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $102,648.86 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $18,154.52 | 2019-2025 | Recarbrio, Zerbaxa |
| Allergan, INC. | $16,510.52 | 2019-2020 | |
| Shionogi INC | $6,736.22 | 2022-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $5,490.17 | 2019-2021 | |
| Astellas Pharma US INC | $905.90 | 2019-2025 | |
| Melinta Therapeutics, LLC | $286.89 | 2023-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Abbott Laboratories | $164.44 | 2025 | Cardiomems |
| Insmed, INC. | $132.61 | 2019 | |
| Recordati_rare_diseases_inc. | $86.10 | 2023-2024 | Panhematin |
| Smith+Nephew, INC. | $50.63 | 2023-2025 | Pico, Grafix |
| Ets Wound Care LLC | $26.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipul Ganatra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.